Annals of Oncology Advance Access published online on October 7, 2008
Annals of Oncology, doi:10.1093/annonc/mdn637
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
Clinic of Medical Oncology, Polytechnic University of the Marche Region, Riuniti Hospital, Ancona, Italy
* Correspondence to: Dr M. Scartozzi, Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy. Tel: +39-715963834; Fax: +39-715964192; E-mail: marioscartozzi{at}libero.it
Background: Arterial hypertension occurring during antiangiogenic therapy has been correlated with the biological inhibition of the vascular endothelial growth factor-related pathway and may represent a possible clinical marker for treatment efficacy. The aim of our study was to retrospectively assess if grades 2–3 hypertension were associated with response to bevacizumab, progression-free survival (PFS) and survival in metastatic colorectal cancer patients treated with first-line bevacizumab.
Patients and methods: Patients with histologically proven, metastatic colorectal cancer receiving bevacizumab as first-line therapy in combination with irinotecan and 5-fluorouracil were eligible for our analysis.
Results: Thirty-nine metastatic colorectal cancer patients were eligible. Eight patients (20%) developed grades 2–3 hypertension. A partial remission was observed in six of eight cases with bevacizumab-related hypertension (75%) and in 10 of 31 (32%) patients with no hypertension (P = 0.04). Median PFS was 14.5 months for patients showing bevacizumab-related hypertension, while it was 3.1 months in those without hypertension (P = 0.04). Median overall survival was not reached in patients with hypertension while it was 15.1 months in the remaining cases (P = 0.11).
Conclusions: Our data indicate that bevacizumab-induced hypertension may represent an interesting prognostic factor for clinical outcome in advanced colorectal cancer patients receiving first-line bevacizumab.
arterial hypertension, bevacizumab, colorectal cancer
Received for publication March 27, 2008. Revision received July 16, 2008. Accepted for publication August 22, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U. A. Matulonis, S. Berlin, P. Ivy, K. Tyburski, C. Krasner, C. Zarwan, A. Berkenblit, S. Campos, N. Horowitz, S. A. Cannistra, et al. Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer J. Clin. Oncol., November 20, 2009; 27(33): 5601 - 5606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Mir, S. Ropert, J. Alexandre, and F. Goldwasser Hypertension as a surrogate marker for the activity of anti-VEGF agents Ann. Onc., May 1, 2009; 20(5): 967 - 970. [Full Text] [PDF]
|
|
|
|
|
|
B. I. Levy Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor Ann. Onc., February 1, 2009; 20(2): 200 - 203. [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- Hypertension-A prognostic factor for patients receiving Bevacizumab ?
- Mark J. Rother
- Annals of Oncology, 11 Feb 2009 [Full text]